Replies to post #1462 on Avid Bioservices Inc (CDMO)

[DewDiligence]

Reading your posts, it’s more apparent than ever that there are a heck of a lot of companies pursing VTA’s and related approaches to cancer treatment. Given the finite pool of patients and, more important, the limited pool of reimbursement dollars, it is mathematically impossible for all of these drug candidates to become big-selling drugs.

Does this make you a tad wary of the economic underpinning of investing in this sector?

[technicalwin]

Katie, too bad that Melton is the best game in town for PPHM right now. Agree that PPHM needs to license but they need credibility to get a good deal. I am hopeful they get some credibility and analyst coverage with some good results from the P1. TW